Eli Lilly And Company

This study tests a new drug called LY4175408 for people with advanced lung, endometrial, or triple-negative breast cancer that has spread. The drug is designed to find and attack cancer cells carrying a specific marker (PTK7). The main goals are to check the drug's safety and see…

This study tests a new medicine called LY3938577 against a standard insulin (degludec) in 100 adults with type 2 diabetes who already use basal insulin. The goal is to see if the new drug helps keep blood sugar in a healthy range more safely and effectively over about 26 weeks. P…

This study tests a once-daily pill called orforglipron against a placebo in 150 teens aged 12-17 who have obesity or are overweight with related health issues. Participants take the pill for about 18 months while continuing healthy lifestyle changes. The goal is to see if the pil…

This study tests a new medicine called brenipatide to see if it can help adults who have recently quit smoking avoid relapsing. About 222 participants will receive either the drug or a placebo for 24 weeks, and researchers will track how many stay smoke-free using carbon monoxide…

This study allows cancer patients who were getting benefit from an experimental drug in a previous Eli Lilly study to keep receiving that drug after the earlier study ends. It is designed for people who have no other good treatment options and whose doctor agrees continued access…

This study tests a new medicine called brenipatide to see if it helps adults with alcohol use disorder drink less and reduce cravings. About 1,100 participants will receive either the drug or a placebo for 56 weeks. The goal is to find a safe and effective treatment to help peopl…

This study is testing several new treatments for adults with moderate to severe ulcerative colitis or Crohn's disease. About 60 participants will be randomly assigned to receive one of the study treatments or a placebo. The goal is to see if these treatments can safely control th…

This early-stage study tests a new medicine called LY4298445 to see if it is safe and tolerable. It involves healthy volunteers and people with lupus or rheumatoid arthritis. Participants receive either the drug or a placebo and are followed for up to a year. The goal is to under…

This study tests an investigational drug called lebrikizumab in about 510 adults with long-term sinus inflammation and nasal polyps. Participants continue using standard steroid nasal spray. The goal is to see if the drug reduces nasal congestion and shrinks polyps over 18 months…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in a previous trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to t…

This study tests whether adding a new targeted medicine (vepugratinib) to two standard cancer drugs can help people with advanced bladder cancer that has a specific genetic change (FGFR3). About 450 adults whose cancer has spread or cannot be removed by surgery will take part. Th…

This study tests a new once-weekly injection called eloralintide to help adults with obesity or overweight lose weight. About 1980 people who do not have type 2 diabetes will take part for up to 75 weeks, with some continuing for 2 more years. The goal is to see if the drug safel…

This study is testing whether adding the drug donanemab to standard care helps people with early Alzheimer's stay independent longer. Researchers will follow about 6,250 participants for over 5 years, tracking when they need more help with daily tasks. The goal is to see if donan…

This study tests a new weekly injection called eloralintide in 900 adults with obesity or overweight who are already taking a weekly incretin drug (like Ozempic or Wegovy) but still have excess weight. Participants will receive either eloralintide or a placebo for about 80 weeks …

This study tests several experimental treatments to help adults with obesity or overweight lose weight and keep it off. About 1,481 participants will receive one of the study drugs or a placebo. The goal is to find safe and effective options for long-term weight management.

This study tests a new drug called LY4005130 in 60 adults with non-segmental vitiligo, a condition that causes white patches on the skin. The drug is given through a vein and compared to a placebo to see if it safely reduces the size of the patches. The trial lasts about 48 weeks…

This study tests whether adding brenipatide to standard schizophrenia medication is safe and effective. About 450 adults with schizophrenia will receive either brenipatide or a placebo for up to 12 months. Researchers will measure changes in body weight, cognitive function, and h…

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and a CDK4/6 inhibitor can better control advanced breast cancer that has a specific genetic change (PIK3CA mutation). About 920 adults with HR+, HER2- breast cancer that has spread and has not bee…

This study tests whether adding an experimental drug called brenipatide to standard addiction treatment (buprenorphine) helps people with opioid use disorder stay off opioids longer. About 465 participants will receive either brenipatide or a placebo injection for up to 144 weeks…

This study tests whether adding a new drug called brenipatide to standard depression treatment can delay the return of major depressive symptoms. About 1000 adults with major depression who are already on stable medication will receive either brenipatide or a placebo as a shot, p…

This study tests a daily pill called orforglipron to see if it can prevent major heart problems (like heart attacks or strokes) and slow kidney disease in people who already have heart or kidney disease. About 7,140 adults will take either the drug or a placebo for up to 5 years.…

This early-stage study tests a new drug called LOXO-435 in people with advanced solid tumors, especially bladder cancer, that have a specific change in the FGFR3 gene. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 535 participan…

This early-stage study tests a new drug called LY4584180 in adults with blood cancers like lymphoma that have not responded to at least two prior treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 460 part…

This study tests a new drug called LY4052031 in people with advanced or metastatic solid tumors, including bladder, breast, and lung cancers. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The trial has two parts: first to find the safest dose, th…

This early-stage study tests a new medicine called LY4086940 in healthy people and those who are overweight or have obesity, with or without type 2 diabetes. The main goal is to check the drug's safety and how the body processes it. About 216 adults will take part, and the study …

This study tests whether brenipatide can reduce asthma attacks and improve breathing in adults with moderate-to-severe asthma that is not well controlled by current treatments. About 531 participants will receive either brenipatide or a placebo for 52 weeks. The goal is to see if…

This study tests whether adding the experimental drug LY3537982 to standard treatments helps people with advanced KRAS G12C-mutant non-small cell lung cancer live longer without their cancer growing. About 1,264 participants will receive either the new combination or standard car…

This study tests a new drug called eltrekibart, given alone or with another drug (mirikizumab), in 140 adults with moderate-to-severe ulcerative colitis. The goal is to see if the treatment can reduce symptoms and help the colon heal. Participants must have tried other treatments…

This study tests whether baricitinib, a daily pill, is safe and works for children aged 1 to under 18 with systemic juvenile idiopathic arthritis (sJIA), a chronic inflammatory disease. About 58 children will receive either baricitinib or a standard injected drug (tocilizumab) to…

This early-stage study tests a new drug called LY3938577 in healthy volunteers and people with type 1 diabetes. Researchers want to see how the drug moves through the body, how safe it is, and how well it controls blood sugar compared to a standard insulin. The study has four par…

This study tests a new drug called brenipatide in 150 healthy adults who are overweight or obese. Participants receive different doses as injections under the skin to see how much weight they lose and if the drug is safe. The study lasts about 42 weeks and is still recruiting.

This study tests a new drug, LY4337713, that delivers radiation directly to cancer cells with a specific protein called FAP. It is for adults with advanced or spread cancers like pancreatic, breast, ovarian, or colorectal cancer. The main goals are to check safety, side effects, …

This early-stage study tests a new drug called LY3954068 in 48 people with mild Alzheimer's symptoms. The drug is given directly into the spinal fluid, either once or twice, to see if it is safe and how it affects Alzheimer's markers. The study lasts up to 100 weeks and includes …

This study looks at whether adding tirzepatide (a weight-loss drug) to standard ixekizumab treatment helps adults with active psoriatic arthritis who are overweight or obese. About 200 participants will receive both medications for up to 12 months. The goal is to see if this comb…

This early-stage study tests a new drug called LY4050784 in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 340 participants will join, and…

This study tests a new medicine called brenipatide to see if it helps people with moderate-to-severe alcohol use disorder drink less and reduce cravings. About 1,100 adults who want to cut down or stop drinking will receive either brenipatide or a placebo for 56 weeks. The main g…

This study tests whether two medications, retatrutide and tirzepatide, can prevent major liver complications like cirrhosis or liver failure in adults with high-risk metabolic fatty liver disease (MASLD). About 4,500 participants will be randomly assigned to receive one of the dr…

This study tests a new weekly injection called LY3457263 in people with type 2 diabetes who still have high blood sugar despite taking stable doses of semaglutide or tirzepatide. About 240 adults will receive either the new drug or a placebo for around 9 months. The main goal is …

This study tests a once-weekly medicine called tirzepatide in 300 teenagers with obesity and at least two weight-related health problems like high blood pressure or prediabetes. Participants will receive the drug or a placebo for about 76 weeks, along with healthy eating and exer…

This early-stage study tests a new drug called LY4256984 in 32 people with ALS. The drug is given directly into the spine to see if it is safe and what side effects it may cause. Researchers will also measure how much drug gets into the blood and spinal fluid. This is a first ste…

This study tests whether adding the experimental drug olomorasib to standard immunotherapy helps people with a specific genetic subtype of non-small cell lung cancer (KRAS G12C mutation). About 700 adults whose cancer was either surgically removed or cannot be removed will receiv…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia or non-Hodgkin lymphoma. About 787 participants who completed an earlier pirtobrutinib study can join to keep receiving treatment or have follow-up visits. The main goal…

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This study tests a drug called baricitinib in children aged 6 to 17 with severe alopecia areata, a condition that causes patchy or total hair loss. The goal is to see if the drug can safely help regrow scalp hair. Participants will take the drug or a placebo for 36 weeks, then ma…

This study tests a new drug, Sofetabart Mipitecan, for people with ovarian, fallopian tube, or peritoneal cancer. Part A includes those whose cancer no longer responds to platinum chemotherapy, and Part B includes those whose cancer still responds. The goal is to see if the new d…

This study tests whether adding tirzepatide (a weight-loss drug) to mirikizumab (an UC treatment) helps people with moderate-to-severe ulcerative colitis who are also overweight or obese. About 350 adults will receive either mirikizumab alone or mirikizumab plus tirzepatide for u…

This study tests a drug called muvalaplin in over 10,000 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease and stroke. Participants either have had a prior heart attack or stroke or are at high risk for a first event. The goal is to see if muvalap…

This study tests whether adding an experimental drug (LY4395089) to the existing treatment mirikizumab works better than mirikizumab alone for adults with moderate-to-severe Crohn's disease. About 60 participants will be followed for 62 weeks to see if the combination improves bo…

This study tests whether baricitinib, a pill, can help preserve the body's ability to make insulin in people newly diagnosed with type 1 diabetes. About 300 children and young adults (ages 1 to under 36) will take either baricitinib or a placebo for 60 weeks. The goal is to see i…

This early-stage study is testing a new drug called LY4064912 to see if it is safe and tolerable for healthy adults and those who are overweight or have obesity. About 144 participants will receive either the drug or a placebo, given as an injection under the skin or into a vein.…

This study is testing a new medicine called LY4006896 to see if it is safe for people with Parkinson's disease. It will involve 127 healthy volunteers and people with Parkinson's. The drug is given through a vein, and researchers will monitor for side effects and measure how the …

This study tests whether adding tirzepatide (a weight-loss drug) to mirikizumab (an anti-inflammatory drug) helps adults with moderate-to-severe Crohn's disease who are also overweight or obese. About 290 participants will receive either mirikizumab alone or mirikizumab plus tirz…

This study tests a new once-weekly medicine called eloralintide to help people with obesity or overweight and type 2 diabetes lose weight. About 1035 adults will receive either the drug or a placebo for around 75 weeks. Researchers will measure changes in body weight, fat, waist …

This study tests whether adding a new drug (LY4268989) to an existing treatment (mirikizumab) helps more people with moderate-to-severe ulcerative colitis reach remission compared to mirikizumab alone. About 252 adults will take part for up to 2 years. The goal is to see if the c…

This study tests whether adding brenipatide to standard bipolar treatment can delay the return of symptoms (relapse) compared to a placebo. About 400 adults with bipolar I or II disorder will receive either brenipatide or a placebo by injection for at least 6 months. The main goa…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with another BTK inhibitor. About 150 adults who completed a prior pirtobrutinib study can join. …

This study tests a drug called mirikizumab in children aged 2 to 17 with moderate to severe Crohn's disease. The goal is to see if it can reduce gut inflammation and improve symptoms like belly pain and diarrhea. About 90 kids will take part, receiving the drug for up to 52 weeks…

This program provides early access to retatrutide for individual patients who have no other treatment options. It is designed for people with serious conditions who cannot join a clinical trial. The goal is to offer a potential treatment before the drug is officially approved.

This study tests a weekly medicine called tirzepatide to help adults with obesity (but no diabetes) lose weight and prevent type 2 diabetes. About 3000 participants will receive either tirzepatide or standard care for up to 5 years. The goal is to see if tirzepatide works better …

This study tests pirtobrutinib, an oral medication, in 58 adults with immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets, raising bleeding risk. The first phase checks safety and side effects; the second compares different doses against a place…

This study tests a new medicine called solbinsiran in 60 adults with severely high triglycerides (a type of blood fat). Participants receive two shots and are monitored to see if the drug safely lowers their triglyceride levels compared to a placebo. The goal is to control the co…

This study looks at how well and how safely the drug mirikizumab works over a long period (about 3 years) in children and teenagers with moderate-to-severe ulcerative colitis or Crohn's disease. About 150 participants who have already been in earlier studies will continue treatme…

This study tests a new drug, STX-478, in people with advanced solid tumors that have a specific genetic mutation (PI3Kα). The drug is given alone or with other cancer treatments. The goal is to see if it is safe and shrinks tumors. About 880 adults with breast cancer or other sol…

This study looks at the long-term safety and effectiveness of the drug baricitinib for children aged 1 to 17 with juvenile idiopathic arthritis (JIA). It includes 190 participants who have already taken baricitinib in a previous study. Researchers will monitor side effects and ho…

This study tests two experimental drugs, macupatide and eloralintide, alone or together, to help adults with obesity or overweight and type 2 diabetes lose weight. About 200 participants will take the drugs or a placebo for 48 weeks. The main goal is to see how much weight they l…

This study tests whether higher doses (3.0 mg and 4.5 mg) of the diabetes drug dulaglutide are safe and work well for teens aged 10 to 17 with type 2 diabetes. About 55 participants will take the drug for around 8 months while doctors monitor side effects, blood sugar levels, and…

This trial is a master protocol that allows researchers to test several new cancer drugs in children and young adults more efficiently. About 105 participants with different types of cancer will join, and each will receive a drug tailored to their disease. The goal is to see how …

This study tests a new medicine called LY4005130 for people with severe alopecia areata, a condition causing significant hair loss. About 60 adults will receive either the drug or a placebo through an IV. The goal is to see if the drug can regrow hair and to check for side effect…

This early-stage study tests a new drug called LY4006895 for safety and how the body processes it. Part A involves healthy volunteers receiving a single dose, while Part B gives multiple doses to people with early Alzheimer's. The goal is to check for side effects and measure dru…

This study tests an oral medication called LY4268989 for adults with moderately to severely active ulcerative colitis. About 1,431 participants will receive either the study drug or a placebo to see if it safely reduces symptoms and leads to remission. The trial lasts up to 108 w…

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…

This study is for adults with moderate-to-severe plaque psoriasis who are also overweight or obese. Researchers want to see if adding the weight-loss drug tirzepatide to the standard psoriasis treatment ixekizumab improves skin clearance and helps people lose at least 10% of thei…

This study tests a new drug called retatrutide in adults with type 2 diabetes who are already on metformin and other oral medications. The goal is to see if retatrutide improves how the body's cells work and responds to insulin compared to a placebo or another drug. About 95 part…

This study tests the safety and effectiveness of tirzepatide in 344 Indian adults with type 2 diabetes or obesity. Participants receive the drug for 46 weeks. Researchers will track side effects, weight loss, and blood sugar control.

This study tests the safety and effectiveness of new medicines to help children and teens with obesity or overweight manage their weight long-term. It includes 125 participants aged 12 to 17 who have already tried lifestyle changes like diet and exercise without enough success. T…

This early-stage study tests a new radioactive dye called [18F]LY4214835 to see if it is safe and how well it lights up tumors on scans. About 41 healthy adults and people with cancer will receive one injection and be followed for 35 days. The goal is to improve cancer imaging, n…

This study is testing whether a blood test that measures a protein called P-tau217 can help doctors make better decisions for people with memory complaints. The study will include 7,000 participants and compare what actions doctors take when they have the blood test results versu…

This study tests whether baricitinib, an oral drug, can delay the start of type 1 diabetes in children aged 1 to 35 months who are at high risk. About 150 participants will receive either the drug or a placebo for up to 5 years. The main goal is to see how long it takes for clini…

This study tests whether a daily pill called orforglipron can reduce episodes of stress urinary incontinence (leaking urine during coughing, exercise, or movement) in women who have obesity or overweight. About 1000 adult women will receive either the drug or a placebo for around…

This study tests a new drug called brenipatide for people with irritable bowel syndrome with constipation (IBS-C). The drug is given as a shot under the skin and is compared to a placebo. The goal is to see if it safely reduces belly pain and improves bowel movements. About 342 a…

This large study aims to find better ways to treat chronic pain from osteoarthritis of the knee, diabetic nerve pain, and long-term low-back pain. Researchers will test several different treatments and compare them to a placebo. The study needs 10,000 adults who have had daily pa…

This study tests a once-daily pill called orforglipron in 800 people who are overweight or have obesity and also have painful knee osteoarthritis. The goal is to see if the drug helps with both weight loss and knee pain over about 74 weeks. Participants will be randomly assigned …

This early-stage study tests a new drug called LY4167586 in 84 people with obesity or overweight who are otherwise healthy. The main goal is to check the drug's safety and how the body processes it after a single dose. Participants will be monitored for about 7 months to track an…

This study tests a once-weekly medicine called eloralintide in 800 adults with moderate-to-severe sleep apnea who are also overweight or have obesity. The goal is to see if it reduces breathing pauses during sleep and helps with weight loss. Some participants use a breathing mach…

This early-stage study tests a new drug called LY4057996 in 124 healthy volunteers and people with type 1 or type 2 diabetes. The main goal is to see if the drug is safe and what side effects it may cause. Participants receive the drug as a shot under the skin or into a vein, and…

This early-stage study tests a new drug called LY4213663 in healthy volunteers and people with rheumatoid arthritis (RA). The main goal is to see if the drug is safe and what side effects it may cause. Researchers will also measure how the drug moves through the body. The study l…

This study tests a single oral dose of an experimental drug, LY4515100, to see if it safely reduces moderate-to-severe pain after wisdom tooth surgery. About 212 adults who need at least two impacted wisdom teeth removed will receive either the drug or a placebo. The main goal is…

This study tests a once-weekly injection called retatrutide to see if it can reduce chronic low back pain and help with weight loss in people who have obesity or overweight. About 586 participants will receive either the drug or a placebo for up to 80 weeks. The goal is to find a…

This study tests whether the experimental drug LY4065967 can safely reduce nerve pain in people with diabetes. About 150 adults with diabetic peripheral neuropathy will receive either the drug or a placebo. The main goal is to see if the drug lowers average pain intensity over ti…

This study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…

This study tests a drug called lebrikizumab for adults with year-round allergies (perennial allergic rhinitis). The goal is to see if it reduces nasal symptoms like sneezing, stuffiness, and itching. About 450 participants will receive either the drug or a placebo, and the study …

This study tests an experimental drug called LY3971297 to see if it is safe and how the body processes it. It includes healthy volunteers, people with obesity and high blood pressure, and those with reduced kidney function. The study involves up to 225 participants and lasts abou…

This study tests an investigational drug called brenipatide for adults with irritable bowel syndrome with diarrhea (IBS-D). About 531 participants will receive either the drug or a placebo injection under the skin for several weeks. The goal is to see if the drug safely reduces d…

This study tests a once-daily pill called orforglipron in about 1205 people with peripheral artery disease (PAD) who have leg pain when walking. The goal is to see if the drug helps them walk farther without pain and improves their quality of life. Participants will be followed f…

This study tests a once-weekly medicine called eloralintide in 900 adults who have both knee osteoarthritis and obesity or overweight. The goal is to see if it reduces knee pain and helps with weight loss over about 75 weeks. Participants will receive either the drug or a placebo…

This study looks at how the drug eloralintide enters the bloodstream and leaves the body in people with severe kidney disease or kidney failure, compared to healthy volunteers. About 28 participants will receive a single shot under the skin. The study lasts about 14 weeks and doe…

This study looks at how the drug LY3537031 enters the bloodstream and leaves the body in people with normal, mild, moderate, or severe liver problems. About 32 adults will receive a single injection under the skin. The goal is to understand safety and drug levels, not to treat a …

This study tests how a single dose of the drug eloralintide is processed by the body in people with mild, moderate, or severe liver damage compared to those with healthy livers. It aims to understand safety and drug levels, not to treat liver disease. About 36 adults will partici…

This early-stage study is testing an experimental drug called LY3867070 in 196 healthy people. The main goal is to see if the drug is safe and what side effects it may cause. Researchers will also measure how the drug moves through the body. No treatment benefit is expected for p…

This study follows 3,400 adults who feel their thinking is normal but may have early Alzheimer's risk based on a blood test. Over 7 years, researchers will measure memory and thinking skills to see how quickly they change. The goal is to better understand who is at risk and how t…

This early-stage study tests the safety of a new drug called LY4066708 in 104 healthy people. Researchers will measure how much drug enters the blood and brain, and how fast the body clears it. The study lasts up to 24 weeks and does not aim to treat any disease, but will help gu…

This early-stage study aims to check if the experimental drug LY4515100 is safe and how it moves through the body. About 40 healthy adults will take either the drug or a placebo. The study involves blood tests and overnight stays, but offers no direct treatment benefit.

This study looks at whether a single injection of the experimental drug mirikizumab works as well as two injections in healthy people. Researchers will check safety and how the body processes the drug. About 450 healthy adults will take part, and the study lasts around 15 weeks p…

This study looks at how lepodisiran enters the blood and leaves the body in people with mild, moderate, or severe liver problems compared to those with healthy livers. About 33 adults will receive a single injection under the skin. The goal is to understand how liver function aff…

This early-stage study tests a new drug called LY4088044 in healthy adults to see if it is safe and how the body handles it. About 104 participants will receive the drug or a placebo, either as a shot under the skin or into a vein. The study lasts up to 92 weeks and focuses on si…